$MRNS: AH take-off - NEWS: Marinus Pharmaceuti
Post# of 22747
Posted On: 06/27/2016 4:47:26 PM
$MRNS: AH take-off - NEWS:
Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
4:05 PM ET 6/27/16 | GlobeNewswire
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the company will host a conference call and live webcast on Tuesday, June 28, 2016 at 9:00 a.m. ET to report the results from the Phase 2 investigator-sponsored, exploratory study evaluating ganaxolone in children with Fragile X Syndrome.
The live webcast can be accessed on the investor page of Marinus' website at http://ir.marinuspharma.com/events.cfm. The conference call can be accessed by dialing 844-277-9448 (domestic) or 336-525-7135 (international) and referencing conference ID number 40705361. A replay will be available on Marinus' website approximately two hours after completion of the event and will be archived for up to 30 days.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety and convenient dosing, to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a CNS-selective GABAA modulator that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone IV is in a Phase 1 clinical trial to treat status epilepticus. Ganaxolone IV is complemented by its oral dose forms, providing the potential for IV-to-oral continuation therapy for patients transitioning from acute care to outpatient settings. Ganaxolone capsule and liquid are being studied in orphan pediatric indications with comorbidities in seizures and behavior disorders - PCDH19 epilepsy and Fragile X Syndrome. For more information visit www.marinuspharma.com.
Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
4:05 PM ET 6/27/16 | GlobeNewswire
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the company will host a conference call and live webcast on Tuesday, June 28, 2016 at 9:00 a.m. ET to report the results from the Phase 2 investigator-sponsored, exploratory study evaluating ganaxolone in children with Fragile X Syndrome.
The live webcast can be accessed on the investor page of Marinus' website at http://ir.marinuspharma.com/events.cfm. The conference call can be accessed by dialing 844-277-9448 (domestic) or 336-525-7135 (international) and referencing conference ID number 40705361. A replay will be available on Marinus' website approximately two hours after completion of the event and will be archived for up to 30 days.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety and convenient dosing, to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders. Ganaxolone is a CNS-selective GABAA modulator that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone IV is in a Phase 1 clinical trial to treat status epilepticus. Ganaxolone IV is complemented by its oral dose forms, providing the potential for IV-to-oral continuation therapy for patients transitioning from acute care to outpatient settings. Ganaxolone capsule and liquid are being studied in orphan pediatric indications with comorbidities in seizures and behavior disorders - PCDH19 epilepsy and Fragile X Syndrome. For more information visit www.marinuspharma.com.
(1)
(0)Scroll down for more posts ▼